Криулин Иван Алексеевич
Scientific Center of Children's Health · 51 works · 84 citations · h-index 4
Top works
- COVID-19-associated secondary hemophagocytic lymphohistiocytosis (cytokine storm syndrome)
- POS1312 DRUG SURVIVAL FOR IL-6 INHIBITOR TOCILIZUMAB: DATA FROM A SINGLE-CENTER OBSERVATION
- Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
- Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial
- Defining Criteria for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
- SARS-CoV-2-NEUTRALISING MONOCLONAL ANTIBODIES: MECHANISM OF ACTION AND RESEARCH RESULTS
- The Efficacy and Safety of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus influenzae Type b Infections in Children with Juvenile Idiopathic Arthritis Without Systemic Manifestations: A Prospective Cohort Study
- Can We Successfully Discontinue Anti-Tumor Necrosis Factor-α Treatment in Children with Non-Systemic Juvenile Idiopathic Arthritis? The Experience of a Tertiary Center
- AB0721 CLINICAL AND LABORATORY CHARACTERISTICS, GENETIC FEATURES OF MACROPHAGE ACTIVATION SYNDROME IN CHILDREN WITH SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS: A SINGLE CENTER EXPERIENCE
- Features of clinical and laboratory manifestations of secondary hemophagocytic syndrome in children with rheumatic diseases developed after a new coronavirus infection (COVID-19)
- Assessment of the safety of the two-component drug of monoclonal antibodies to SARS-CoV-2 (tixagevimab+cilgavimab) for pre-exposure prophylaxis of the new coronavirus infection in children with rheumatic diseases
- Hemophagocytic lymphohistiocytosis: mechanisms of development, clinical manifestations, and treatments
- Efficacy and safety of canakinumab therapy in patients with systemic juvenile idiopathic arthritis. Results of a retrospective cohort study
- Experience with the JAK-kinase inhibitor upadacitinib in children with rheumatic diseases
- Efficacy and safety of different withdrawal regimens for tumor necrosis factor (TNF)-alpha inhibitors in long-term remission of non-systemic juvenile idiopathic arthritis: results of the prospective simple randomized trial
- Features of clinical and laboratory manifestations of undifferentiated autoinflammatory diseases in patients – carriers of variants in genes associated with autoinflammation
- Toward Personalized Withdrawal of TNF-α Inhibitors in Non-Systemic Juvenile Idiopathic Arthritis: Predictors of Biologic-Free Remission and Flare
- Effectiveness and Safety of Rituximab in Patients with Refractory Juvenile Idiopathic Arthritis: A Tertiary Center Experience
- Особенности течения полиартикулярного ювенильного идиопатического артрита серопозитивного по ревматоидному фактору
- Treatment of secondary hemophagocytic syndrome in patients with systemic juvenile idiopathic arthritis. Results of a cohort retrospective study